Cantex and Headlamp Partner to Advance Azeliragon for MS Depression and Fatigue

Cantex Pharmaceuticals and Headlamp Health announced in a press release a collaboration to apply Headlamp's Lumos AI platform to the clinical development of azeliragon for severe depression and fatigue in patients with multiple sclerosis.

Headlamp's Lumos AI is a neuro symbolic, multi agent platform designed for neuropsychiatric drug development. It integrates biological, behavioral, biomarker, and clinical data into a unified intelligence layer, helping teams identify responder and non responder subtypes earlier and refine trial design.

Under the agreement, Headlamp Health will deploy Lumos AI to analyze data across azeliragon's development program. Azeliragon is an oral, blood brain barrier penetrant RAGE inhibitor in clinical development, targeting neuroinflammatory processes linked to depression and fatigue in multiple sclerosis patients.